Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2015. “Our product development programs advanced meaningfully during the third quarter with an NDA submission to the Food and Drug Administration for our lead product candidate, DEXTENZA for a post-surgical o
